2024 World Conference on Lung Cancer (WCLC) - Posters-P2.07A.04 Clinical Relevance of PD-L1 Expression Levels in Surgically Resected EGFR-Mutant Lung Adenocarcinoma Patients (CReGYT-01 Study)

P2.07A.04 Clinical Relevance of PD-L1 Expression Levels in Surgically Resected EGFR-Mutant Lung Adenocarcinoma Patients (CReGYT-01 Study)

Back to course

Pdf Summary

The CReGYT-01 study conducted by Fumihiko Kinoshita and colleagues investigated the clinical relevance of programmed cell death-ligand 1 (PD-L1) expression in surgically resected lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) mutations. Despite using biomarkers like PD-L1 expression and EGFR mutation to guide treatment strategies in LUAD, the impact of PD-L1 expression in EGFR mutant LUAD was hitherto unclear.<br /><br />This study compiled a real-world dataset from 21 centers in Japan, encompassing the years 2015 to 2018, and included 4,181 enrolled patients who underwent anatomical lung resections. Out of these, 847 tumors had their PD-L1 status evaluated.<br /><br />The key findings from the univariable and multivariable analyses revealed that high PD-L1 expression is associated with poorer recurrence-free survival, independent of the EGFR mutation status or type. However, PD-L1 levels appeared not to influence the overall survival of patients with EGFR mutant LUAD. This indicates that while PD-L1 can be an indicator of recurrence risk, it does not necessarily predict overall life expectancy for these patients.<br /><br />The study acknowledges its limitations, notably the exclusion of patients treated with adjuvant Osimertinib. It suggests that further large-scale studies including such cases are needed to enhance the understanding of PD-L1's significance in this context.<br /><br />This research underscores the complexity of predicting outcomes for EGFR mutant LUAD patients, highlighting the necessity for personalized medicine approaches, and understanding molecular intricacies to better tailor treatments. The contributions of the CReGYT group, who gathered extensive patient data, were crucial for these insights, albeit without any specific external funding.

Asset Subtitle

Fumihiko Kinoshita

Meta Tag

Speaker Fumihiko Kinoshita

Topic Early-Stage NSCLC

Keywords

CReGYT-01 study

PD-L1 expression

lung adenocarcinoma

EGFR mutations

recurrence-free survival

overall survival

personalized medicine

molecular intricacies

real-world dataset

Japan